Sign In
Buy CLLS
$2.75
-0.100 (-3.51%)
At Close: Jul 31, 2026
Monthly information on share capital and company voting rights
08:30pm, Monday, 22'nd Aug 2022 GlobeNewswire Inc.
(Article 223-16 of General Regulation of the French financial markets authority) (Article 223-16 of General Regulation of the French financial markets authority)
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
08:30pm, Monday, 22'nd Aug 2022 GlobeNewswire Inc.
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)
Iovance (IOVA) Q2 Earnings Miss, Lifileucel BLA on Track
04:13pm, Friday, 05'th Aug 2022 Zacks Investment Research
Iovance Biotherapeutics (IOVA) reports a wider-than-expected second-quarter loss. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Cellectis S.A. (CLLS) CEO Andre Choulika on Q2 2022 Results - Earnings Call Transcript
02:36pm, Friday, 05'th Aug 2022
Cellectis S.A. (NASDAQ:CLLS ) Q2 2022 Earnings Conference Call August 5, 2022 8:00 AM ET Company Participants Arthur Stril - Chief Business Officer Andre Choulika - Chief Executive Officer Bing Wang -
Cellectis publie ses résultats financiers du deuxième trimestre 2022
08:32pm, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
NEW YORK, 04 août 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de gén
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022
08:30pm, Thursday, 04'th Aug 2022 GlobeNewswire Inc.
Cellectis reçoit l’accord de la FDA pour démarrer un essai clinique sur UCART20x22, son premier produit candidat conçu et fabriqué en interne, pour le traitement des tumeurs malignes à cellules B
08:30pm, Monday, 01'st Aug 2022 GlobeNewswire Inc.
NEW YORK, 01 août 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de gén
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies
08:30pm, Monday, 01'st Aug 2022 GlobeNewswire Inc.
NEW YORK, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform t
Why Beam Therapeutics Stock Dipped Today
05:38pm, Monday, 01'st Aug 2022 The Motley Fool
A clinical hold is weighing on the biotech's shares today.
Cellectis to Report Second Quarter 2022 Financial Results
08:30pm, Thursday, 28'th Jul 2022 GlobeNewswire Inc.
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-savin
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2022 le vendredi 5 août à 14h00 CET
08:30pm, Thursday, 28'th Jul 2022 GlobeNewswire Inc.
NEW YORK, 28 juill. 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de gé
Cellectis to Report Second Quarter 2022 Financial Results
04:30pm, Thursday, 28'th Jul 2022
NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving
Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?
11:53am, Wednesday, 20'th Jul 2022 Zacks Investment Research
Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Cellectis dévoile dans Nature Communications de nouvelles cellules CAR T universelles immuno-évasives dotées d'une persistance potentiellement améliorée
09:20am, Thursday, 30'th Jun 2022 GlobeNewswire Inc.
NEW YORK, 30 juin 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de géno
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence
09:19am, Thursday, 30'th Jun 2022 GlobeNewswire Inc.
NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform
